51
|
Garin E, Lesimple T. Intérêt de la tomographie d’émission de positons au 18F-fluorodésoxyglucose (TEP-FDG) dans la prise en charge des syndromes CAPI. ONCOLOGIE 2008. [DOI: 10.1007/s10269-008-0988-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
52
|
Newbold KL, Partridge M, Cook G, Sharma B, Rhys-Evans P, Harrington KJ, Nutting CM. Evaluation of the role of 18FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer. Acta Oncol 2008; 47:1229-36. [PMID: 18661420 DOI: 10.1080/02841860802256483] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND AND PURPOSE As techniques for radiotherapy delivery have developed, increasingly accurate localisation of disease is demanded. Functional imaging, particularly PET and its fusion with anatomical modalities, such as PET/CT, promises to improve detection and characterisation of disease. This study evaluated the impact of (18)FDG-PET/CT on radiotherapy target volume definition in head and neck cancer (HNC). MATERIALS AND METHODS The PET/CT scans of patients with HNC were used in a radiotherapy planning (RTP) study. The gross tumour volume (GTV), clinical target volume (CTV) and planning target volume (PTV) were defined conventionally and compared to those defined using the PET/CT. Data were reported as the median value with 95% confidence intervals. RESULTS Eighteen patients were consented, 9 had known primary tumour site, 9 presented as unknown primary. In nine cases where the primary site was known, the combined primary and nodal GTV (GTVp+n) increased by a median of 6.1cm(3) (2.6, 12.2) or 78% (18, 313), p=0.008 with CTV increasing by a median of 10.1cm(3) (1.3, 30.6) or 4% (0, 13) p=0.012. In 9 cases of unknown primary the GTVp+n increased by a median 6.3 cm(3) (0.2, 15.7) or 61% (4, 210), p=0.012, with CTV increasing by a median 155.4 cm(3) (2.7, 281.7) or 95% (1, 137), p=0.008. CONCLUSION (18)FDG-PET revealed disease lying outside the conventional target volume, either extending a known area or highlighting a previously unknown area of disease, including the primary tumour in 5 cases. We recommend PET/CT in the RTP of all cases of unknown primary. In patients with a known primary, although the change in volume was statistically significant the clinical impact is less clear. (18)FDG-PET can also show areas within the conventional target volume that are hypermetabolic which may be possible biological target volumes for dose escalation studies in the future.
Collapse
|
53
|
Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 2008; 19:731-44. [PMID: 18925401 PMCID: PMC2816234 DOI: 10.1007/s00330-008-1194-4] [Citation(s) in RCA: 198] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2008] [Revised: 08/11/2008] [Accepted: 09/05/2008] [Indexed: 01/26/2023]
Abstract
The aim of this study was to systematically review and meta-analyze published data on the diagnostic performance of combined 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the detection of primary tumors in patients with cancer of unknown primary (CUP). A systematic search for relevant studies was performed of the PubMed/MEDLINE and Embase databases. Methodological quality of the included studies was assessed. Reported detection rates, sensitivities and specificities were meta-analyzed. Subgroup analyses were performed if results of individual studies were heterogeneous. The 11 included studies, comprising a total sample size of 433 patients with CUP, had moderate methodological quality. Overall primary tumor detection rate, pooled sensitivity and specificity of FDG-PET/CT were 37%, 84% (95% CI 78–88%) and 84% (95% CI 78–89%), respectively. Sensitivity was heterogeneous across studies (P = 0.0001), whereas specificity was homogeneous across studies (P = 0.2114). Completeness of diagnostic workup before FDG-PET/CT, location of metastases of unknown primary, administration of CT contrast agents, type of FDG-PET/CT images evaluated and way of FDG-PET/CT review did not significantly influence diagnostic performance. In conclusion, FDG-PET/CT can be a useful method for unknown primary tumor detection. Future studies are required to prove the assumed advantage of FDG-PET/CT over FDG-PET alone and to further explore causes of heterogeneity.
Collapse
Affiliation(s)
- Thomas C Kwee
- Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands.
| | | |
Collapse
|
54
|
Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature. Nucl Med Commun 2008; 29:666-73. [PMID: 18677207 DOI: 10.1097/mnm.0b013e328302cd26] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The objectives of this study were to evaluate the diagnostic accuracy of fluorodeoxyglucose (FDG)-PET and FDG-PET/computed tomography (CT) in the detection of primary tumors in patients presenting with carcinoma of unknown primary (CUP) unidentified by conventional workup, and to compare the statistical difference between the FDG-PET and FDG-PET/CT. Twenty-eight studies (involving a total of 910 patients) published between 1990 and 2007 were reviewed. These studies evaluated the role of FDG-PET and FDG-PET/CT in the detection of unknown primary tumors after physical examination and conventional workup failed to detect a primary tumor. Systematic methods were used to identify, select, and evaluate the methodological quality of the studies as well as to summarize the overall findings of sensitivity, specificity, and detection capacity of the primary tumor. The overall sensitivity and specificity of FDG-PET in detecting unknown primary tumors were 0.78 [95% confidence interval (CI): 0.72-0.84)] and 0.79 (95% CI: 0.74-0.83), respectively. Furthermore, FDG-PET detected 28.54% of tumors that were not apparent after CUP failed to be detected by conventional workup. Data were collected on the locations of primary tumors detected by FDG-PET in 17 studies and detected by FDG-PET/CT in seven studies. Tumors from the base of the tongue accounted for 20.7% (six of 29) of all false-positive FDG-PET scans, corresponding to a false-positive rate of 28.6% (six of 29), much higher than tumors from the others. FDG-PET exhibited a lower sensitivity with respect to the tumors at the base of the tongue and tonsils, which was 68.2 and 76.7%, respectively. In the eight studies with 430 patients diagnosed with CUP by FDG-PET/CT, 31.4% (n=135) of primary tumors were detected. The pooled sensitivity and specificity were 0.81 (95% CI: 0.74-0.87) and 0.83 (95% CI: 0.78-0.87), respectively. FDG-PET and FDG-PET/CT can detect primary tumors that went undetected by physical examination and conventional workup. FDG-PET exhibited lower sensitivity with respect to the tumors at the base of the tongue and the tonsils.
Collapse
|
55
|
Neben K, Hübner G, Folprecht G, Jäger D, Krämer A. Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome. DEUTSCHES ARZTEBLATT INTERNATIONAL 2008; 105:733-40. [PMID: 19623297 PMCID: PMC2696976 DOI: 10.3238/arztebl.2008.0733] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/02/2008] [Accepted: 06/24/2008] [Indexed: 02/07/2023]
Abstract
INTRODUCTION The term cancer of unknown primary site (CUP) syndrome is used to describe malignancies in which a complete diagnostic work-up detects metastases in the absence of an identifiable primary tumor. METHODS Based on a selective literature review, national and international guidelines, and the experience of the "Arbeitskreis CUP-Syndrom der Arbeitsgemeinschaft Internistische Onkologie der Deutschen Krebsgesellschaft" (CUP Syndrome Committee of the Medical Oncology Joint Working Group of the German Cancer Society), developments in the diagnosis and treatment of CUP syndrome are reported. RESULTS Most patients diagnosed with CUP have an unfavorable prognosis, with a life expectancy of less than 12 months. Nevertheless, it is important to identify subsets of patients in whom specific treatment offers the chance of long-term survival or even full recovery. DISCUSSION Only rigorous further development of diagnostic tools and treatment protocols will enable an improvement of the poor prognosis of patients with CUP syndrome. Specific molecular treatment strategies have shown promising results.
Collapse
Affiliation(s)
- Kai Neben
- Medizinische Klinik und Poliklinik V, Universität Heidelberg
| | | | | | - Dirk Jäger
- Nationales Centrum für Tumorerkrankungen, Heidelberg
| | - Alwin Krämer
- Medizinische Klinik und Poliklinik V, Universität Heidelberg
- Klinische Kooperationseinheit für Molekulare Hämatologie und Onkologie, des Deutschen Krebsforschungszentrums und der Medizinischen Klinik und Poliklinik V der Universität Heidelberg, Im Neuenheimer Feld 581, 69120 Heidelberg
| |
Collapse
|
56
|
Hueser CN, Nguyen NC, Osman M, Havlioglu N, Patel AJ. Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans. World J Surg Oncol 2008; 6:102. [PMID: 18817561 PMCID: PMC2564932 DOI: 10.1186/1477-7819-6-102] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2007] [Accepted: 09/25/2008] [Indexed: 11/11/2022] Open
Abstract
Background Extrapulmonary small cell carcinoma (EPSCC) involving the brain is a rare manifestation of an uncommon tumor type. Case presentation We report a 59 year-old Caucasian female diagnosed with an EPSCC involving the left parietal lobe without detectable extracranial primary tumor followed by serial positron emission tomography/computed tomography (PET/CT) imaging. Histopathological examination at both initial presentation and recurrence revealed small cell carcinoma. Serial PET/CT scans of the entire body failed to reveal any extracranial [18F]2-fluoro-2-deoxy-D-glucose (FDG) avid lesions at either diagnosis or follow-up. Conclusion Chemotherapy may show a transient response in the treatment of EPSCC. Further studies are needed to help identify optimal treatment strategies. Combination PET/CT technology may be a useful tool to monitor EPSCC and assess for an occult primary malignancy.
Collapse
Affiliation(s)
- Christopher N Hueser
- Department of Internal Medicine, Division of Hematology and Oncology, St, Louis University Hospital, St Louis, MO 63110, USA.
| | | | | | | | | |
Collapse
|
57
|
Pinilla I, Rodríguez-Vigil B, Gómez-León N. Integrated FDG PET/CT: Utility and Applications in Clinical Oncology. Clin Med Oncol 2008; 2:181-98. [PMID: 21892279 PMCID: PMC3161686 DOI: 10.4137/cmo.s504] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Accurate diagnosis and staging are essential for an optimal management of cancer patients. Positron emision tomography with 2-deoxy-2-fluorine-18-fluoro-D-glucose (18FDG-PET) and, more recently, 18FDG-PET/computed tomography (18FDG-PET/CT) have emerged as powerful imaging tools in oncology, because of the valuable functional information they provide. The combined acquisition of PET and CT has synergistic advantages over its isolated constituents and minimizes their limitations. It decreases examination times by 25%–40%, leads to a higher patient throughput and unificates two imaging procedures in a single session. There is evidence that 18FDG-PET/CT is a more accurate test than either of its components for the evaluation of various tumors. It is a particularly valuable tool for detection of recurrence, especially in asymptomatic patients with rising tumor markers and those with negative or equivocal findings on conventional imaging tests. Yet, there are some limitations and areas of uncertainty, mainly regarding the lack of specificity of the 18FDG uptake and the variable 18FDG avidity of some cancers. This article reviews the advantages, limitations and main applications of 18FDG-PET/CT in oncology, with especial emphasis on lung cancer, colorectal cancer, lymphomas, melanoma and head and neck cancers.
Collapse
|
58
|
Shah GV, Wesolowski JR, Ansari SA, Mukherji SK. New directions in head and neck imaging. J Surg Oncol 2008; 97:644-8. [PMID: 18493943 DOI: 10.1002/jso.21022] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Computerized tomography (CT) and magnetic resonance imaging (MRI), positron emission tomography (PET) and the hybrid modality of PET/CT are sensitive and reliable tools for detection and staging of head and neck cancers. This article describes the role of PET/CT in initial staging of head and neck squamous cell carcinoma, the utility of CT/MR perfusion imaging in qualitative analysis of tumor tissue, and the usefulness of diffusion weighted MR and dynamic contrast-enhanced MR imaging in head and neck oncological imaging.
Collapse
Affiliation(s)
- Gaurang V Shah
- Department of Radiology, University of Michigan, Ann Arbor, Michigan 48109, USA.
| | | | | | | |
Collapse
|
59
|
Johansen J, Buus S, Loft A, Keiding S, Overgaard M, Hansen HS, Grau C, Bundgaard T, Kirkegaard J, Overgaard J. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck 2008; 30:471-8. [PMID: 18023031 DOI: 10.1002/hed.20734] [Citation(s) in RCA: 127] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND The benefit of a complementary fluorodeoxyglucose-positron emission tomography (FDG-PET) scan to standard workup for carcinoma of unknown primary (CUP) and metastatic neck lesions was prospectively studied. METHODS Sixty-seven patients underwent standardized diagnostic workup according to national guidelines including panendoscopies, multiple mucosal biopsies, and diagnostic CT/MRI scans. Median follow-up was 40 months (range, 2-65 months). RESULTS In 60 eligible patients, FDG-PET indicated a primary tumor or metastatic disease in 30 patients (50%). Additional investigations confirmed a primary tumor in 18 patients: hypopharynx in 5, oropharynx in 5, nasopharynx in 2, lung in 1, axilla in 1, bone in 1, rectum in 1, as well as multiple metastatic lesions from CUP in 2 patients. In retrospect, MRI was able to detect 1 of the PET-detected primaries, leading to an overall detection rate of PET of 29% in CUP. A therapeutic change of treatment was made in 25% as a consequence of FDG-PET. PET before panendoscopy demonstrated fewer false-positive pathological foci. CONCLUSION FDG-PET is a valuable tool in addition to conventional extensive workup in CUP and neck metastases. Consequently, FDG-PET is now recommended as an early diagnostic modality in the workup of these patients.
Collapse
Affiliation(s)
- Jørgen Johansen
- Department of Oncology, Odense University Hospital, Odense, Denmark.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
60
|
Prasad V, Ambrosini V, Alavi A, Fanti S, Baum RP. PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism. PET Clin 2008; 3:355-79. [DOI: 10.1016/j.cpet.2009.04.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
61
|
|
62
|
|
63
|
Abstract
Carcinoma of unknown primary is uncommon, estimated to represent only 3% to 5% of all head and neck cancers. Squamous cell carcinoma accounts for 70% to 90% of these lesions, most commonly from sites in the upper aerodigestive tract, including tonsils, base of tongue, nasopharynx, and piriform sinus. Magnetic resonance, computed tomography (CT), and positron emission tomography all play a role in the assessment of patients with an unknown primary. The location of a metastatic lymph node may give an indication of the primary tumor site, and knowledge of lymph node drainage patterns is important for anyone evaluating these patients. Magnetic resonance and CT are both used for evaluation for extracapsular nodal disease, perineural tumor spread, osseous skull base or perivertebral space involvement, and vascular invasion, findings that seriously impact treatment and prognosis. Positron emission tomography/CT also plays a significant role in detecting primary tumor sites and identifying distant metastatic disease.
Collapse
Affiliation(s)
- Theodore S Donta
- Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA.
| | | |
Collapse
|
64
|
|
65
|
Haug AR, Schmidt GP, Klingenstein A, Heinemann V, Stieber P, Priebe M, la Fougère C, Becker C, Hahn K, Tiling R. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers. J Comput Assist Tomogr 2007; 31:629-34. [PMID: 17882045 DOI: 10.1097/01.rct.0000284394.83696.42] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE The value of combined positron emission tomography (PET)/computed tomography (CT) in the follow-up of patients with breast cancer with elevated tumor markers but without proven metastases or local recurrence was assessed. METHODS Thirty-four women underwent PET/CT. The PET and CT images were first analyzed separately; fused findings were then interpreted, blinded to the results of the other modalities. The results of CT, PET, and PET/CT were compared with each other and correlated to the final diagnosis. RESULTS The PET/CT identified 149 malignant foci in 24 patients (71%). The CT detected 96 of these foci in 18 patients, whereas PET identified 124 foci in 17 patients. Differences between CT and PET were not significant. Differences between PET/CT and CT (P < 0.01) and PET/CT and PET (P < 0.01) were significant. The person-based sensitivity of PET/CT, PET, and CT was 96%, 88% and 96%, respectively. Specificity of PET/CT, PET, and CT was 89%, 78%, and 78%, respectively. CONCLUSIONS The PET/CT is a valuable modality for the follow-up of patients with breast cancer and elevated levels of tumor markers.
Collapse
|
66
|
Abstract
Anatomic imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) have been used for many years in clinical oncology. The emergence of positron emission tomography (PET) more than a decade ago was a major breakthrough in the early diagnosis of malignant lesions, as it was based on tumour metabolism and not on anatomy. The merger of both techniques into one thanks to PET-CT cameras has made this technology the most important tool in the management of cancer patients. PET/CT with 18F-FDG is increasingly being used for staging, restaging and treatment monitoring for cancer patients with different types of tumours (lung, breast, colorectal, lymphoma, melanoma, head and neck etc.). At many institutions, PET/CT has replaced separately acquired PET and CT examinations for many oncologic indications. This replacement has occurred despite the fact that only a relatively small number of well designed prospective studies have verified imaging findings against the gold standard of histopathologic tissue evaluation. However, a large number of studies have used acceptable reference standards, such as pathology, imaging and other clinical follow-up findings, for validating PET/CT findings. The impact on the management of patients and the benefits from the information obtained from this anatomo-metabolic procedure justify the term "clinical oncology based on PET-CT" as a new concept to be applied in clinical practice.
Collapse
Affiliation(s)
- A Maldonado
- Centro PET Recoletas La Milagrosa, Madrid, Spain.
| | | | | | | |
Collapse
|
67
|
Veit-Haibach P, Luczak C, Wanke I, Fischer M, Egelhof T, Beyer T, Dahmen G, Bockisch A, Rosenbaum S, Antoch G. TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging 2007; 34:1953-62. [PMID: 17717661 DOI: 10.1007/s00259-007-0564-5] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2007] [Accepted: 07/25/2007] [Indexed: 11/24/2022]
Abstract
PURPOSE PET/CT, PET+CT, and CT were compared concerning accuracies in TNM staging and malignancy detection in head and neck cancer. The impact of PET/CT compared to the other imaging modalities on therapy management was assessed. MATERIALS AND METHODS Fifty-five patients with suspected head and neck primary cancer underwent whole-body FDG-PET/CT. PET/CT and PET+CT were evaluated by a nuclear medicine physician and a radiologist; CT was evaluated by two radiologists, PET by two nuclear physicians. Histopathology served as the standard of reference. Differences between the staging modalities were tested for statistical significance by McNemar's test. RESULTS Overall TNM-staging and T-staging with PET/CT were more accurate than PET+CT and CT alone (p < 0.05). PET/CT was marginally more accurate than CT alone in N-staging (p = 0.04); no statistically significant difference was found when compared to PET+CT for N-staging. PET/CT altered further treatment in 13 patients compared to CT only and in 7 patients compared to PET+CT. CONCLUSION Combined PET/CT proved to be partly more accurate in assessing the overall TNM-stage than CT and PET+CT. These results were based on a higher accuracy concerning the T-stage, mainly in patients with metallic implants and marginally the N-stage. Therapy decisions have been influenced in a substantial number of patients. PET/CT might be considered as a first line diagnostic tool in patients with suspected primary head and neck cancer.
Collapse
Affiliation(s)
- Patrick Veit-Haibach
- Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstrasse 55, Essen, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
68
|
Garin E, Prigent-Lejeune F, Lesimple T, Barge ML, Rousseau C, Devillers A, Bouriel C, Habiba MT, Bernard AM, Bridji B, Resche I. Impact of PET-FDG in the diagnosis and therapeutic care of patients presenting with metastases of unknown primary. Cancer Invest 2007; 25:232-9. [PMID: 17612933 DOI: 10.1080/07357900701206331] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
We carried out a study to evaluate the contribution of positron emission tomography with (18)F-fluorodeoxyglucose (PET-FDG) in the diagnosis and therapeutic care of patients presenting with metastases of unknown primary. PET-FDG was prospectively performed in 51 patients. The PET-FDG data were confirmed histologically or by a follow-up on average at 13 months. PET-FDG identified the primary in 24 percent of cases, and detected the presence of additional metastases in 41 percent of cases. PET-FDG led to a therapeutic modification for 12 patients (24 percent). Furthermore, the therapeutic impact seems more marked in localized forms than in the multifocal. This broad exploratory study confirms the important role of PET-FDG in the diagnosis and therapeutic management of patients with metastases of unknown primary.
Collapse
Affiliation(s)
- Etienne Garin
- UPRES EA 3890/Department of Medical Imagery, Centre Eugène Marquis, Rennes, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
69
|
Pepper K, Jaowattana U, Starsiak MD, Halkar R, Hornaman K, Wang W, Dayamani P, Tangpricha V. Renal cell carcinoma presenting with paraneoplastic hypercalcemic coma: a case report and review of the literature. J Gen Intern Med 2007; 22:1042-6. [PMID: 17443359 PMCID: PMC2219737 DOI: 10.1007/s11606-007-0189-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2006] [Revised: 02/02/2007] [Accepted: 03/08/2007] [Indexed: 10/23/2022]
Abstract
We report a case of a 62-year-old woman with renal cell carcinoma (RCC) presenting with a hypercalcemia-induced coma. A laboratory evaluation indicated nonparathyroid-mediated hypercalcemia with an initial serum calcium level of 18.6 mg/dL. Our patient's parathyroid hormone (PTH)-related peptide level was undetectable. Initial imaging was negative, but PET scan identified a mass in the upper pole of the left kidney. Our patient underwent partial nephrectomy, and the mass was identified as RCC on final pathology. After surgery, her hypercalcemia resolved and PTH returned to normal limits. This case report describes a patient with RCC with the unusual presentation of hypercalcemic coma. We review the differential diagnosis of malignant hypercalcemia and the evaluation of hypercalcemia occurring with RCC. This case illustrates the need to carefully review and interpret all available data, especially when conventional testing in the work-up of hypercalcemia is unrevealing.
Collapse
Affiliation(s)
- Kara Pepper
- Division of General Internal Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA USA
| | - Uraporn Jaowattana
- Division of Endocrinology, Diabetes and Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle NE, WMRB 1301, Atlanta, GA USA
| | - Michael D. Starsiak
- Department of Radiology, Emory University School of Medicine, Atlanta, GA USA
| | - Raghuueer Halkar
- Department of Radiology, Emory University School of Medicine, Atlanta, GA USA
| | - Kelly Hornaman
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA USA
| | - Wenli Wang
- Division of Endocrinology, Diabetes and Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle NE, WMRB 1301, Atlanta, GA USA
| | - Priya Dayamani
- Division of Endocrinology, Diabetes and Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle NE, WMRB 1301, Atlanta, GA USA
| | - Vin Tangpricha
- Division of Endocrinology, Diabetes and Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle NE, WMRB 1301, Atlanta, GA USA
| |
Collapse
|
70
|
Fencl P, Belohlavek O, Skopalova M, Jaruskova M, Kantorova I, Simonova K. Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary. Eur J Nucl Med Mol Imaging 2007; 34:1783-92. [PMID: 17541584 DOI: 10.1007/s00259-007-0456-8] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2006] [Accepted: 03/13/2007] [Indexed: 11/30/2022]
Abstract
PURPOSE The aim of the study was to determine the accuracy of [(18)F]fluorodeoxyglucose (FDG) PET/CT in the search for the primary and the presence of a malignancy. The prognostic value of FDG-PET/CT information was tested. METHODS A total of 190 patients were retrospectively analysed: 82 with histologically proven metastases (HPM) and 108 with clinical suspicion of the presence of a malignancy (CSM). The sensitivity and specificity were determined. Overall survival was calculated to evaluate the prognostic value of the FDG-PET/CT findings. RESULTS In the search for the primary, the sensitivity and specificity were 62.0% and 81.9%, respectively. In the search for the presence of a malignancy, the sensitivity and specificity were 93.6% and 85.7%, respectively. Between the HPM and CSM groups, no significant difference in sensitivity and specificity was found either in the search for the primary or in the search for the presence of a malignancy. No significant difference in the sensitivity and specificity was found between 78 patients who were investigated by contrast-enhanced FDG-PET/CT and the remaining patients. A significantly shorter overall survival was found among patients with positive FDG-PET/CT findings compared with patients with negative findings (p = 0.00001); no significant difference in survival was found between the HPM and the CSM group (p = 0.770). CONCLUSION FDG-PET/CT imaging is very helpful in the search for the presence of a malignancy in patients with carcinoma of unknown primary syndrome. FDG-PET/CT is less accurate in identifying exactly the site of a primary. Discovery of a hypermetabolic lesion was associated with the worst survival rate.
Collapse
Affiliation(s)
- Pavel Fencl
- PET Center, Na Homolce Hospital, Roentgenova 2, 150 30 Prague 5, Czech Republic.
| | | | | | | | | | | |
Collapse
|
71
|
Wartski M, Le Stanc E, Gontier E, Vilain D, Banal A, Tainturier C, Pecking AP, Alberini JL. In search of an unknown primary tumour presenting with cervical metastases: Performance of hybrid FDG-PET–CT. Nucl Med Commun 2007; 28:365-71. [PMID: 17414886 DOI: 10.1097/mnm.0b013e3280708edf] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVES In patients with cervical lymph node metastases from unknown primary tumour (UPT), the primary tumour is frequently localized in the head and neck area. Because the detection of the primary tumour is of importance to optimize the patient's management and allows a targeted therapy, the performances of hybrid positron emission tomography-computed tomography (PET-CT) using fluorodeoxyglucose (FDG) were evaluated in a retrospective study. METHODS Thirty-eight consecutive patients with cervical lymph node metastases, and in whom the primary was not detected by the comprehensive diagnostic work-up including endoscopy and conventional imaging methods, were referred for a PET-CT scan. RESULTS PET-CT was positive with an increased FDG focal uptake suggesting the potential primary site in 68% of patients (26/38), which guided the biopsies during a second rigid panendoscopy in 17 of these 26 patients: 13 primary tumours were then histologically proven. PET-CT showed distant lesions in three patients. It had treatment-related implications in 23/38 patients (60%), consisting of modification of radiation planning, surgery or abstention from surgery. CONCLUSION Hybrid FDG-PET-CT is helpful for the detection of a potential head and neck primary tumour. Furthermore, hybrid FDG-PET-CT has the ability to diagnose occult or distant second tumour and metastatic disease and modify patient management.
Collapse
Affiliation(s)
- Myriam Wartski
- Nuclear Medicine Department of Cancer Research Center Rene Huguenin, Saint-Cloud, France.
| | | | | | | | | | | | | | | |
Collapse
|
72
|
Abstract
Treatment of cancer is reliant on identifying the organ of origin. However, in a significant minority of cases, the primary site is never identified. This paper reviews the diagnostic work-up and therapeutic management for patients presenting with unknown primary cancer, including the role of tumour markers, conventional pathology and positron emission tomography imaging. It is important to identify atypical presentations of known tumour types, such as extragonadal germ cell tumours, lymphomas and breast cancer. The results from chemotherapy trials performed in patients with unknown primary cancer are summarised. Few trials have included > 100 patients, and most are non-randomised. There is no clear standard of care from the available data, and no trials of chemotherapy versus best supportive care have been performed. Platinum is the mainstay of treatment regimens, and from the regimens tested, a taxane seems to be among the best of the cytotoxics to combine with platinum in terms of both tolerability and efficacy. There is no data to favour a three-drug combination over a two-drug combination. To improve on existing treatment, molecular techniques may provide a means to identify the organ of origin, and/or to select appropriate targeted therapies. Further research is needed to improve knowledge on the biology of cancer from an unknown primary and to develop more effective treatment.
Collapse
Affiliation(s)
- Anne C Armstrong
- Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK.
| | | |
Collapse
|
73
|
Abstract
Functional imaging with positron emission tomography (PET) is playing an increasingly important role in the diagnosis and staging of malignant disease, image-guided therapy planning, and treatment monitoring. PET with the labeled glucose analogue fluorine 18 fluorodeoxyglucose (FDG) is a relatively recent addition to the medical technology for imaging of cancer, and FDG PET complements the more conventional anatomic imaging modalities of computed tomography (CT) and magnetic resonance imaging. CT is complementary in the sense that it provides accurate localization of organs and lesions, while PET maps both normal and abnormal tissue function. When combined, the two modalities can help both identify and localize functional abnormalities. Attempts to align CT and PET data sets with fusion software are generally successful in the brain; other areas of the body is more challenging, owing to the increased number of degrees of freedom between the two data sets. These challenges have recently been addressed by the introduction of the combined PET/CT scanner, a hardware-oriented approach to image fusion. With such a device, accurately registered anatomic and functional images can be acquired for each patient in a single scanning session. Currently, over 800 combined PET/CT scanners are installed in medical institutions worldwide, many of them for the diagnosis and staging of malignant disease and increasingly for monitoring of the response to therapy. This review will describe some of the most recent technologic developments in PET/CT instrumentation and the clinical indications for which combined PET/CT has been shown to be more useful than PET and CT performed separately.
Collapse
Affiliation(s)
- Todd M Blodgett
- Department of Radiology, University of Pittsburgh Medical Center, 200 Lothrop St, Pittsburgh, PA 15213, USA.
| | | | | |
Collapse
|
74
|
|
75
|
Fakhry N, Lussato D, Jacob T, Giorgi R, Giovanni A, Zanaret M. Comparison between PET and PET/CT in recurrent head and neck cancer and clinical implications. Eur Arch Otorhinolaryngol 2007; 264:531-8. [PMID: 17203307 DOI: 10.1007/s00405-006-0225-5] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2006] [Accepted: 12/08/2006] [Indexed: 11/25/2022]
Abstract
The aim of this retrospective study was to compare the diagnostic accuracy between positron emission tomography (PET) and combined PET/computed tomography (PET/CT) in the detection of recurrent head and neck squamous cell carcinoma (HNSCC) and to evaluate the degree of interobserver agreement. Thirty-two patients who had undergone curative treatment for HNSCC and who presented with a suspicion of recurrent local disease were studied with fluoro-2-deoxy-D-glucose (FDG)-PET imaging. All patients had undergone an inconclusive conventional workup (nasofibroscopy, CT scan and/or MRI). PET and PET/CT were reviewed by two nuclear medicine physicians independently. Performances of PET and PET/CT were compared using biopsy and/or clinical follow-up of at least 8 months as gold-standard. ROC curves were employed for statistical analysis. Out of 32 patients, 18 (56%) had a local recurrence. Intraclass correlation coefficients were strong (>90) and statistically significant (P < 0.0001) for the two reviewers in all cases. The sensitivity, specificity and accuracy of PET were found to be 94%, between 36 and 50% and between 69 and 75%, respectively, depending on the consideration of equivocal cases. Results for PET/CT were found to be 94, 57 and 78%. The utility scores of PET and PET/CT were 0.72 and 0.78, respectively. PET/CT could have a direct impact on patient care with the avoidance of 8/14 (57%) unnecessary invasive procedures (panendoscopy under general anaesthesia). Combined PET/CT is more accurate than PET alone for detection of recurrent HNSCC. The findings of this study are reinforced by the strong interobserver agreement in the interpretation of the results.
Collapse
Affiliation(s)
- Nicolas Fakhry
- Department of Head and Neck Surgery and Federation of Otolaryngology, La Timone University Hospital Center, Marseille Cedex 05, France.
| | | | | | | | | | | |
Collapse
|
76
|
Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109:292-9. [PMID: 17167760 DOI: 10.1002/cncr.22410] [Citation(s) in RCA: 120] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND The authors conducted a comprehensive review of the efficacy of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography (FDG-PET) in the detection of primary tumors in patients with disseminated carcinoma of unknown primary site. METHODS Ten studies (involving a total of 221 patients) tat were published between 1998 and 2006 were reviewed. Each study evaluated the role of FDG-PET in the detection of unknown primary tumors after a conventional diagnostic workup. Although 94% of patients had a single site of metastases, the studies otherwise were very heterogeneous in the studied population, study design, and additional diagnostic workup. RESULTS In 41% of patients, FDG-PET detected primary tumors that were not apparent after conventional workup. In this group of patients, the overall sensitivity, specificity, and accuracy rates of FDG-PET in detecting unknown primary tumors were 91.9%, 81.9%, and 80.5%, respectively. FDG-PET imaging also led to the detection of previously unrecognized metastases in 37% of patients. Lung cancers represented 59% of the detected tumors. FDG-PET had a notably high false-positive rate (58.3%) in tumors of the lower digestive tract. FDG-PET altered the clinical management in 34.7% of patients. Most of those patients (53%) received specific chemotherapy for lung and pancreatic cancers; whereas 12% received specific therapy for breast, ovarian, and prostate cancers; and 14% underwent surgery with curative intent. CONCLUSIONS FDG-PET was an efficient method for detecting primary tumors that were undetected by other modalities and was sensitive for the detection of previously unrecognized metastases. FDG-PET significantly changed clinical management in approximately one-third of the patients studied.
Collapse
Affiliation(s)
- Pascal Sève
- Department of Internal Medicine, Hôtel Dieu, Hospices Civils de Lyon, Lyon, France.
| | | | | | | | | |
Collapse
|
77
|
Basu S, Alavi A. FDG-PET in the clinical management of carcinoma of unknown primary with metastatic cervical lymphadenopathy: shifting gears from detecting the primary to planning therapeutic strategies. Eur J Nucl Med Mol Imaging 2006; 34:427-8. [PMID: 17195072 DOI: 10.1007/s00259-006-0313-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2006] [Accepted: 10/14/2006] [Indexed: 11/29/2022]
|
78
|
Conessa C, Clément P, Foehrenbach H, Poncet JL. [Positron emission tomography in head and neck squamous cell carcinomas]. ACTA ACUST UNITED AC 2006; 123:227-39. [PMID: 17185920 DOI: 10.1016/s0003-438x(06)76672-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
18F-Fluorodeoxyglucose positron emission tomography (PET) is an imaging modality which is becoming increasingly esential in oncology, especially in the management of head and neck squamous cell carcinomas (SCC). The most common uses of the PET are listed in this thematic study: initial staging, cervical lymph node metastases from an unknown primary tumor and post-therapeutic follow-up. The advantages and drawbacks of this imaging tool are exposed here according to both our experience and data from the literature. Decision schemes are suggested for each use so as to optimize the use of this imaging modality in the management of these SCC. Other fields of application for the PET are mentioned, such as the in-progress evaluation of response to chemotherapy, the interest of this imaging tool in radiotherapy as well as current biochemical developments concerning new tracers.
Collapse
Affiliation(s)
- C Conessa
- Service d'ORL et de Chirurgie de la Face et du Cou, Hôpital d'Instruction des Armées du Val de Grâce, 74 boulevard Port Royal, 75230 Paris Cedex 05.
| | | | | | | |
Collapse
|
79
|
Sironi S, Picchio M, Landoni C, Galimberti S, Signorelli M, Bettinardi V, Perego P, Mangioni C, Messa C, Fazio F. Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence. Eur J Nucl Med Mol Imaging 2006; 34:472-9. [PMID: 17106701 DOI: 10.1007/s00259-006-0251-y] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2006] [Accepted: 07/20/2006] [Indexed: 11/26/2022]
Abstract
PURPOSE The purpose of this study was to prospectively determine the diagnostic accuracy of PET/CT in the detection of recurrence in patients with treated uterine cancers. METHODS Twenty-five women, ranging in age from 37 to 79 years (mean 58.9 years), who underwent primary surgical treatment for either a cervical or an endometrial cancer met the inclusion criterion of the study, which was suspicion of recurrence based on results of routine follow-up procedures. PET/CT was performed after administration of 18F-fluorodeoxyglucose (FDG); two readers interpreted the images in consensus. Histopathological findings or correlation with results of subsequent clinical and imaging follow-up examinations served as the reference standard. Diagnostic accuracy of PET/CT was reported in terms of the proportion of correctly classified patients and lesion sites. RESULTS Tumour recurrence was found at histopathological analysis or follow-up examinations after PET/CT in 14 (56%) of the 25 patients. Patient-based sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PET/CT for detection of tumour recurrence were 92.9%, 100.0%, 100.0%, 91.7% and 96.0%, respectively. Lesion site-based sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PET/CT were 94.7%, 99.5%, 94.7%, 99.5% and 99.0%, respectively. CONCLUSION This preliminary study shows that PET/CT may be an accurate method for the evaluation of recurrence in patients who have been treated for uterine cancers and are undergoing follow-up.
Collapse
Affiliation(s)
- Sandro Sironi
- School of Medicine, University of Milano-Bicocca, Milan, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
80
|
Sorgho-Lougue LC, Luciani A, Kobeiter H, Zelek L, Malhaire C, Deux JF, Brun B, Piedbois P, Rahmouni A. Adenocarcinomas of unknown primary (ACUP) of the mediastinum mimicking lymphoma: CT findings at diagnosis and follow-up. Eur J Radiol 2006; 59:42-8. [PMID: 16504446 DOI: 10.1016/j.ejrad.2006.01.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2005] [Accepted: 01/24/2006] [Indexed: 10/25/2022]
Abstract
OBJECTIVE To describe the computed tomography (CT) features at diagnosis and after treatment of adenocarcinoma of unknown primary (ACUP) mimicking lymphoma of the mediastinum. METHODS Fifteen patients with pathologically proven ACUP and with primarily mediastinal involvement were initially referred to the Hematologic Department of our institution with a suspected diagnosis of lymphoma, and accounted for our study population. Presenting symptoms and baseline biological values were analyzed. All thoraco-abdominal CT studies were reviewed for the location and size of the mediastinal involvement and associated findings. Follow-up chest CT was performed in 14 patients after radiotherapy, chemotherapy or surgical treatment. RESULTS The most frequent CT feature was a large anterior and middle mediastinal mass (67%), with no calcification. Associated findings included the presence of lung nodules (40%), compression of large mediastinal vessels (33%) and pleural effusion (27%). Follow-up CT, performed in 14 cases, suggested partial or complete responses in 7 patients (50%) 4 weeks after the treatment onset. CONCLUSIONS Mediastinal ACUP is a differential diagnosis of large mediastinal masses and is frequently associated with lung nodules and mediastinal vascular compression.
Collapse
Affiliation(s)
- Leonie Claudine Sorgho-Lougue
- Department of Radiology, Centre Hospitalo-Universitaire Henri Mondor, Imagerie Medicale, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Créteil, France
| | | | | | | | | | | | | | | | | |
Collapse
|
81
|
Sève P, Stankovic K, Charhon A, Broussolle C. Les carcinomes de primitif inconnu. Rev Med Interne 2006; 27:532-45. [PMID: 16545500 DOI: 10.1016/j.revmed.2006.01.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2005] [Accepted: 01/06/2006] [Indexed: 10/25/2022]
Abstract
PURPOSE Carcinoma of unknown primary site is a common clinical syndrome, accounting for 2% of cancer patients. Diagnosis is a recurrent challenge for internists. Treatment is difficult and prognosis is still poor. This review presents one synthesis of diagnosis strategies and therapeutic trials. It envisages the interest of new molecular biology methods as well as therapeutic perspectives. CURRENT KNOWLEDGE AND KEY POINTS Pathologic examination completed with immunohistochemical tests, and, depending on cases, with electron microscopy, cytogenetics, and molecular biology is a key-point for diagnosis. Diagnosis work-up, based on histological type and on individualization of some clinical presentation, proceeds in three steps. Positron emission tomography is recommended when a curative treatment is planed, particularly in cases of isolated metastasis. Functional status analysed using the performance status and simple biologic parameters (serum lactate dehydrogenase, serum alkaline phosphatase) permit us to assess prognosis. Chemotherapy is offered for patients with a good general health status. FUTURE PROSPECTS AND PROJECTS Further evaluation of positron emission tomography, as well as cost-benefit analyses, is warranted. Further randomised trials are necessary to determine the optimal chemotherapy regimen in good-risk patients and the interest of chemotherapy in patients with poor-risk disease. Gene expression profiling and proteomic evaluation, as well as pharmacogenomic offer new investigation fields.
Collapse
Affiliation(s)
- P Sève
- Service de médecine interne, Hôtel-Dieu, hospices civils de Lyon, 1, place de l'Hôpital, 69288 Lyon cedex 02, France.
| | | | | | | |
Collapse
|
82
|
Fakhry N, Jacob T, Paris J, Barberet M, Mundler O, Giovanni A, Zanaret M. [Contribution of 18-F-FDG PET for detection of head and neck carcinomas with an unknown primary tumor]. ACTA ACUST UNITED AC 2006; 123:17-25. [PMID: 16609665 DOI: 10.1016/s0003-438x(06)76634-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVES To evaluate the usefulness of fusioning positron emission tomography with computed tomography (PET/CT) for the detection of head and neck carcinomas of unknown primary. METHODS This prospective study included 20 patients with cervical lymph node of squamous cell carcinoma of unknown primary after standard initial workup (nasofibroscopy and CT scan of the chest and head and neck). Patients underwent PET/CT and panendoscopy of the upper airways and upper digestive tract with PET/CT directed biopsies. The follow-up was 6 months minimum in all patients. RESULTS A potential primary tumor was found in 10 of the 20 cases and confirmed by histology in 7 cases (3 bases of tongue, 1 tonsillar pillar, 1 vallecula, 1 tonsillar fossa, 1 piriform sinus). Four of these seven patients presented a normal endoscopy (diagnosis was made with submucosal PET/CT directed biopsies). PET/CT was normal in 10 of 20 cases with 3 false negatives. The sensitivity of PET/CT was 70%, the specificity was 70% and the accuracy was 70%. CONCLUSION PET/CT seems to be of interest in the detection of head and neck carcinoma of unknown primary. PET/CT detected 15% of unknown primary tumors with treatment-related implications.
Collapse
Affiliation(s)
- N Fakhry
- Service d'ORL et de Chirurgie Cervico-Faciale du Professeur Zanaret, CHU La Timone, 264, rue Saint Pierre, 13385 Marseille Cedex 05.
| | | | | | | | | | | | | |
Collapse
|
83
|
Abstract
Over the past six years, PET/CT has spread rapidly and replaced conventional PET. Although PET/CT is a combination of PET for functional information and CT for morphological information, their combination is synergistic. PET/CT fusion images result in higher diagnostic accuracy with fewer equivocal findings. This results in a greater impact on cancer diagnosis. With attenuation correction performed by the CT component, PET/CT can provide higher quality images over shorter examination times than conventional PET. As with all modalities, PET/CT has several characteristic artifacts such as misregistration due to respiration, overattenuation correction due to metals, etc. Awareness of these pitfalls will help the imaging physician use PET/CT effectively in daily practice.
Collapse
|
84
|
Schmidt GP, Haug AR, Schoenberg SO, Reiser MF. Whole-body MRI and PET-CT in the management of cancer patients. Eur Radiol 2006; 16:1216-25. [PMID: 16538426 DOI: 10.1007/s00330-006-0183-8] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2005] [Revised: 01/24/2006] [Accepted: 01/27/2006] [Indexed: 12/22/2022]
Abstract
Mortality rate, prognosis, and treatment outcome of cancer patients depend strongly on the detection of malignancy at an early stage and efficient monitoring of the disease. Multimodality diagnostic approaches are now widely applied for tumor detection, staging, and follow-up. However, the introduction of whole-body imaging modalities into clinical practice has substantially expanded diagnostic options. PET-CT has increased diagnostic accuracy by providing "anatometabolic" information by fusing tumor glucose-uptake measures from the PET examination and accurate delineation of anatomical structures given by spiral CT. Since PET-CT is associated with high doses of ionizing radiation, it is used in mainly tumor staging and screening within the scope of tertiary prevention. Here promising results have been reported for various tumor entities. MRI provides excellent tissue contrast, detailed morphological information and lack of ionizing radiation. MRI has been employed for the assessment of focal pathologies in specific anatomical regions. Whole-body MRI scanners using multiple receiver channels with parallel acquisition techniques now allow tumor screening from head to toe within substantially shorter examination times and without compromises in image resolution. We report our experience with these two novel techniques and discuss their benefits and drawbacks in terms of systemic tumor screening.
Collapse
Affiliation(s)
- Gerwin P Schmidt
- Department of Clinical Radiology, University Hospitals Grosshadern, Ludwig Maximilian University, Marchioninistrasse. 15, 81377 Munich, Germany.
| | | | | | | |
Collapse
|
85
|
Even-Sapir E, Lerman H, Gutman M, Lievshitz G, Zuriel L, Polliack A, Inbar M, Metser U. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 2006; 33:541-52. [PMID: 16491423 DOI: 10.1007/s00259-005-0056-4] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2005] [Accepted: 12/03/2005] [Indexed: 12/14/2022]
Abstract
PURPOSE The purpose of the study was to determine the general and organ-specific presentation of incidental primary tumours on PET-CT. METHODS PET-CT reports of 2,360 consecutive patients were reviewed and revealed 156 lesions suspicious for a new unexpected malignancy, in 151 patients. One hundred and twenty of these lesions, in 115 patients, were further assessed, by biopsy (n=84 patients) or by clinical and imaging follow-up (n=31 patients) for a mean of 17+/-4 months (range 12-25 months). RESULTS Forty-four unexpected malignancies were found in 41 of the study patients (1.7%). Twenty-seven of the 44 incidental tumours were identified on the basis of their location, which was uncommon for metastasis of the known malignancy. Eight were detected as a result of either the difference in FDG avidity of the known malignancy and the incidental lesion or the presence of an incidental non-FDG-avid mass on the CT part of the study. Four tumours were synchronous carcinomas in patients with known colorectal malignancy, three were identified by virtue of the discordant response to treatment compared with the known primary tumour and two were detected as new sites of disease after a prolonged disease-free period. There was organ variability in the positive predictive values (PPV) of PET-CT findings for incidental primary malignancy or pre-malignant lesions: 62% for colonic lesions, 54% for lung lesions and 24% for thyroid lesions. CONCLUSION Incidental primary tumours may be identified on PET-CT based on their location, FDG avidity, response to therapy and time of appearance. The PET and CT parts of the study appear to complement each other and assist in identification of these incidental tumours.
Collapse
Affiliation(s)
- Einat Even-Sapir
- Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv, 64239, Israel.
| | | | | | | | | | | | | | | |
Collapse
|
86
|
Chin BB, Chang PPL. Gastrointestinal malignancies evaluated with (18)F-fluoro-2-deoxyglucose positron emission tomography. Best Pract Res Clin Gastroenterol 2006; 20:3-21. [PMID: 16473798 DOI: 10.1016/j.bpg.2005.08.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
(18)F-fluoro-2-deoxyglucose positron emission tomography has demonstrated high accuracy in the staging and evaluation of colorectal and esophageal carcinomas. FDG PET is demonstrating increasing utility in a number of other gastrointestinal tumours and clinical scenarios. The established clinical indications for its use, the diagnostic accuracy, and limitations will be reviewed. Data on the emerging indications and limitations for pancreatic, hepatocellular, and gastric carcinomas, as well as gastrointestinal stromal tumours, cholangiocarcinoma, and carcinoma of unknown primary will also be briefly discussed. The use of combined PET-CT is demonstrating further improvements in diagnostic accuracy.
Collapse
Affiliation(s)
- Bennett B Chin
- Division of Nuclear Medicine, Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA.
| | | |
Collapse
|
87
|
Juergens KU, Weckesser M, Stegger L, Franzius C, Beetz M, Schober O, Heindel W, Wormanns D. Tumor staging using whole-body high-resolution 16-channel PET-CT: does additional low-dose chest CT in inspiration improve the detection of solitary pulmonary nodules? Eur Radiol 2006; 16:1131-7. [PMID: 16450084 DOI: 10.1007/s00330-005-0080-6] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2005] [Revised: 10/15/2005] [Accepted: 10/28/2005] [Indexed: 11/30/2022]
Abstract
For optimal image fusion between CT and F-18-FDG-PET, the acquisition of CT images is performed in mild expiratory suspension, which might compromise the detection of lung metastases. This study aimed at evaluating the influence of expiration on the detection of solitary pulmonary nodules (SPN) and at assessing if additional inspiratory low-dose CT (I-LDCT) of the chest can improve the detection of potential lung metastases performing whole-body 16-channel PET-CT. Sixty-six patients with malignant tumors underwent PET-CT: contrast-enhanced CT was acquired during mild expiration and was used for fusion with PET images; additionally, chest I-LDCT was performed at deep inspiration. Two radiologists reported all SPN detected at I-LDCT and the expiratory CT scan independently. Overall, 53% of 128 SPN (mean: 3.8+/-0.2 mm) were detected at both respiratory states: 51 SPN only at I-LDCT, and 9 nodules only at expiratory CT. Of the SPN, 117/128 were classified as certain; 45 of those were additionally detected at I-LDCT, and 6 nodules at expiratory CT. A 100% detection rate was reached in SPN >4 mm at I-LDCT versus >8 mm at expiratory CT (all P<0.001). Additional I-LDCT of the chest significantly improves the detection of SPN at whole-body F-18-FDG-PET-CT and thus is recommended as part of the standard protocol for oncological patients.
Collapse
Affiliation(s)
- K U Juergens
- Department of Clinical Radiology, University of Muenster, Albert-Schweitzer-Strabe 33, 48149 Muenster, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
88
|
Hauth EAM, Antoch G, Stattaus J, Kuehl H, Veit P, Bockisch A, Kimmig R, Forsting M. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol 2006; 56:263-8. [PMID: 16233894 DOI: 10.1016/j.ejrad.2005.04.006] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2004] [Revised: 04/01/2005] [Accepted: 04/04/2005] [Indexed: 01/14/2023]
Abstract
PURPOSE To assess the usefulness and reliability of integrated whole-body positron emission tomography/computed tomography (PET/CT) in patients in whom recurrent ovarian cancer is suspected. METHODS Integrated whole-body PET/CT imaging was performed in 19 patients with suspected ovarian cancer recurrence. CT, PET and fused PET/CT images were evaluated separately and imaging results were compared with pathological findings and clinical follow-up after 6 months. RESULTS Of the 19 patients studied, 11 were found to have recurrent cancer. In 8 of these 11 patients, recurrence was diagnosed by CT, PET and fused PET/CT. In the remaining three patients, only PET and PET/CT showed a recurrent tumour, while CT was negative. Twelve localisations of ovarian cancer recurrence could be detected by CT, 17 by PET and 18 by PET/CT. In one patient with pulmonary metastases in CT and in the CT component of PET/CT, PET was negative. In the case of three metastases in the diaphragm, the spleen and the thoracic wall, respectively, the determination of the exact localisation was only possible by fused PET/CT. CONCLUSION In patients with recurrent ovarian cancer, PET/CT detects more lesions than PET or CT alone. PET/CT permits the exact anatomical localisation of pathologic tracer uptake and can thus direct further treatment to the precise site of tumour recurrence. Hence, PET/CT should be considered for follow-up of patients with ovarian cancer.
Collapse
Affiliation(s)
- Elke A M Hauth
- Department of Diagnostic and Interventional Radiology, University Hospital Essen, Hufelandstrasse 55, D-45122 Essen, Federal Republic of Germany.
| | | | | | | | | | | | | | | |
Collapse
|
89
|
Griffeth LK. Use of PET/CT scanning in cancer patients: technical and practical considerations. Proc (Bayl Univ Med Cent) 2005; 18:321-30. [PMID: 16252023 PMCID: PMC1255942 DOI: 10.1080/08998280.2005.11928089] [Citation(s) in RCA: 110] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
This overview of the oncologic applications of positron emission tomography (PET) focuses on the technical aspects and clinical applications of a newer technique: the combination of a PET scanner and a computed tomography (CT) scanner in a single (PET/CT) device. Examples illustrate how PET/CT contributes to patient care and improves upon the previous state-of-the-art method of comparing a PET scan with a separate CT scan. Finally, the author presents some of the results from studies of PET/CT imaging that are beginning to appear in the literature.
Collapse
Affiliation(s)
- Landis K Griffeth
- Department of Radiology, Baylor University Medical Center, and the North Texas Clinical PET Institute, Dallas, Texas 75246, USA.
| |
Collapse
|
90
|
Wechalekar K, Sharma B, Cook G. PET/CT in oncology—a major advance. Clin Radiol 2005; 60:1143-55. [PMID: 16223611 DOI: 10.1016/j.crad.2005.05.018] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2005] [Revised: 04/15/2005] [Accepted: 05/27/2005] [Indexed: 12/12/2022]
Abstract
The concept of hardware fusion between positron emission tomography (PET) and computed tomography (CT) has only been introduced commercially in the last 4 years. The advantages of this combined technique over PET alone have become obvious. There is increasing evidence to suggest that PET/CT adds complementary information in staging, re-staging and follow-up in oncology patients, leading to changes in management plans. The present paper is a review of the strengths, weaknesses, current evidence and future directions of this technique.
Collapse
Affiliation(s)
- K Wechalekar
- Department of Nuclear Medicine and PET, Royal Marsden Hospital, Sutton, Surrey, UK
| | | | | |
Collapse
|
91
|
Frank SJ, Chao KSC, Schwartz DL, Weber RS, Apisarnthanarax S, Macapinlac HA. Technology Insight: PET and PET/CT in head and neck tumor staging and radiation therapy planning. ACTA ACUST UNITED AC 2005; 2:526-33. [PMID: 16205772 DOI: 10.1038/ncponc0322] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2005] [Accepted: 08/19/2005] [Indexed: 12/25/2022]
Abstract
The evolving utilization of functional imaging, mainly 2-[18F]fluoro-2-deoxyglucose (18FDG) imaging, with positron emission tomography (PET) and PET/CT, is profoundly altering head and neck tumor staging approaches, radiation treatment planning, and follow-up management. Tumor-node-metastasis staging with PET/CT has improved the characterization of patient disease versus CT, MRI, or PET alone, thereby affecting patient disease management. Therefore, the utilization of PET/CT is appropriate for head and neck cancer staging in the initial presentation and in the recurrent setting. In the setting of radiation therapy treatment planning, PET-directed tumor volume contouring is not ready for clinical practice without further technological improvements in imaging specificity/sensitivity and resolution. Patient or organ motion might interfere with the accuracy of anatomical co-alignment, and variability in defining the threshold of imaging signals on PET images can affect the contour of the biological tumor volume. The use of PET/CT for staging and detecting both primary and recurrent head and neck cancer is valuable; however, its application in radiation treatment planning should be viewed as investigational.
Collapse
Affiliation(s)
- Steven J Frank
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | | | | | | | | |
Collapse
|
92
|
Menda Y, Graham MM. Update on 18F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Imaging of Squamous Head and Neck Cancers. Semin Nucl Med 2005; 35:214-9. [PMID: 16150243 DOI: 10.1053/j.semnuclmed.2005.05.001] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
This article summarizes the recent literature in (18)F-fluorodeoxyglucose/positron emission tomography (FDG-PET) imaging of head and neck cancers and extends the previous review in this area by Schöder and Yeung in the July 2004 issue of Seminars in Nuclear Medicine. Positron emission tomography/computed tomography (PET-CT) imaging is now used widely but has not been adequately evaluated for head and neck cancer. Its accuracy in initial staging is better than CT but may be similar to magnetic resonance imaging. It is not sufficiently accurate in the N0 neck to rule out nodal metastases but may be appropriate if sentinel node mapping is performed in patients with PET studies showing no nodal disease. PET imaging is beginning to be used in radiotherapy treatment planning, where it makes a significant difference by identifying malignant normal size nodes, extent of viable tumor, and distant disease. PET continues to be useful in carcinoma of unknown primary in identification of the primary site. Overall success is around 27% after all other modalities have failed. FDG-PET is being used frequently to assess response to therapy and for surveillance thereafter. The major controversy is when to image after radiotherapy or combined chemo-radiotherapy. One month seems to be too early. The ideal time seems to be 3 to 4 months to avoid both false-positive and false-negative studies. The growing use of PET-CT studies in head and neck cancer will certainly make a significant difference in the treatment and outcome in this disease.
Collapse
Affiliation(s)
- Yusuf Menda
- Department of Radiology, University of Iowa, Iowa City, IA 52242, USA.
| | | |
Collapse
|
93
|
Polyzoidis KS, Miliaras G, Pavlidis N. Brain metastasis of unknown primary: A diagnostic and therapeutic dilemma. Cancer Treat Rev 2005; 31:247-55. [PMID: 15913895 DOI: 10.1016/j.ctrv.2005.03.006] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The diagnosis of a brain metastasis is usually made during the routine follow up examinations of patients with known cancer, who are under the care of oncology departments. The involvement of the neurosurgeon depends on the philosophy and referral patterns of each oncology group. Patients with brain metastases of unknown primary (BMUP) are much more likely to seek the help of a neurosurgeon or a neurologist before contacting an oncologist, because the presenting clinical features originate from the brain. BMUPs are almost equal in numbers to brain primaries and differ from regular cerebral metastases regarding their site of origin, which will remain unknown in about 50% despite vigorous investigation. The clinical picture is similar to that of primary brain tumours but they seem to show different areas of predilection in the brain parenchyma. By reviewing the literature we are presenting the epidemiology, clinical presentation, diagnostic workup and treatment plan for this group of patients.
Collapse
Affiliation(s)
- Konstantinos S Polyzoidis
- Department of Neurosurgery, Medical School, University of Ioannina, P.O. Box 1186, Post code 45110, Ioannina, Greece.
| | | | | |
Collapse
|